Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis.
Fiche publication
Date publication
janvier 2021
Journal
Therapeutic advances in medical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland
Tous les auteurs :
Monnet I, Vergnenègre A, Robinet G, Berard H, Lamy R, Falchero L, Vieillot S, Schott R, Ricordel C, Chouabe S, Thomas P, Gervais R, Madroszyk A, Abdiche S, Chiappa AM, Greillier L, Decroisette C, Auliac JB, Chouaïd C,
Lien Pubmed
Résumé
The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases (aBMs) are not well established. This study investigates whether deferring BR until cerebral progression was superior to upfront BR for patients with aNSCLC and aBM.
Mots clés
bevacizumab, cerebral metastasis, management, non-small–cell lung cancer, pemetrexed, radiotherapy
Référence
Ther Adv Med Oncol. 2021 ;13:17588359211006983